as the medulla (Figure 15-1, A) . Structures that are located at the corticomedullary junction extend into the kidney hilum and are called papillae. Each papilla is enclosed by a minor calyx that collectively communicates with the major calyces to form the renal pelvis. The renal pelvis collects urine flowing from the papillae and passes it to the bladder via the ureters. Vascular flow to the kidneys is provided by the renal artery, which branches directly from the aorta. This artery subdivides into segmental branches to perfuse the upper, middle, and lower regions of the kidney. Further subdivisions account for the arteriole-capillary-venous network, or vas recta. The venous drainage of the kidney is provided by a series of veins leading to the renal vein and ultimately to the inferior vena cava.
The kidney's functional unit is the nephron (see Figure  15 -1, B), and each kidney is made up of approximately one million nephrons. Each nephron consists of Bowman's capsule, which surrounds the glomerular capillary bed; the proximal convoluted tubule; the loop of Henle; and the distal convoluted tubule, which empties into the collecting ducts. The glomerulus is a unique network of capillaries that is suspended between afferent and efferent arterioles enclosed within Bowman's capsule and that serves as a filtering funnel for waste. The filtrate drains from the glomerulus into the tubule, which alters the concentration along its length by various processes to form urine. The glomerulus funnels ultrafiltrate to the remaining portion of the nephron, or renal tubule. Following filtration, the second step of urine formation is the selective reabsorption of filtered substances, which occurs along the length of the tubule via active and passive transport processes.
Each day, the kidneys excrete approximately 1.5 to 2.5 L of urine.Although the removal of toxic and waste products from the blood remains their major role, the kidneys are also essential for the production of hormones such as vitamin D and erythropoietin and for the modulation of salt and water excretion. The major functions of the kidney are summarized in Table 15-1. Once destroyed, nephrons do not regenerate. However, the kidney compensates for the loss of nephrons by hypertrophy of the remaining functioning units. This theory, often referred to as the intact nephron hypothesis, maintains that 
▼ FLUIDS, ELECTROLYTES, AND pH HOMEOSTASIS
With advancing nephron destruction, water and electrolyte regulation becomes increasingly more difficult. Adaptations to sudden shifts in intake occur slowly, resulting in wide swings in water and solute concentrations. The first clinical sign of diminished renal function is a decreased ability to concentrate the urine (isosthenuria). As a result of this inability to conserve water, dehydration ensues. With early renal insufficiency, sodium is also lost in the urine. This loss is often independent of the amount of water lost. As renal disease progresses, volume overload leading to hypertension and congestive heart failure can be serious sequelae. When glomerular filtration becomes markedly diminished, the distal tubule can no longer secrete sufficient potassium, leading to hyperkalemia.
In a healthy body, the acid-base balance is maintained via buffers, breathing, and the amounts of acid or alkaline wastes in the urine; this is because the daily load of endogenous acid is excreted into the urine with buffering compunds such as phosphates. As the glomerular filtration rate (GFR) progressively decreases, the tubular excretory capacity for positive hydrogen (H + ) ions is overwhelmed because renal ammonia production becomes inadequate. In its early phases, the resultant acidosis usually has a normal anion gap. As the kidney deteriorates, metabolically derived acids accumulate, leading to an increase in the anion gap. Clinically, this metabolic acidosis is manifested as anorexia, nausea, fatigue, weakness, and Kussmaul's respiration (a deep gasping respiration similar to that observed in patients with diabetic ketoacidosis).
▼ DIAGNOSTIC PROCEDURES IN RENAL DISEASE

Serum Chemistry
In the presence of renal dysfunction, changes in homeostasis are reflected in serum chemistry. Sodium, chloride, blood urea nitrogen (BUN), glucose, creatinine, carbon dioxide, potassium, phosphate, and calcium levels provide a useful tool to evaluate the degree of renal impairment and disease progression. Serum creatinine and BUN are often important markers to the GFR. Both of these products are nitrogenous waste products of protein metabolism that are normally excreted in the urine, but they may increase to toxic levels in the presence of renal dysfunction. A characteristic profile of changes occurs with advancing renal dysfunction, including elevations in serum creatinine, BUN, and phosphate, compared to low levels of serum calcium. Laboratory findings commonly seen in renal disease are summarized in Table 15 -2.
Urinalysis
The most important aspects of urine examination in patients with renal disease include the detection of protein or blood in the urine, determination of the specific gravity or osmolality, and microscopic examination. The hallmarks of renal dysfunction detected by urinalysis are hematuria and proteinuria. Hematuria (the presence of blood in the urine) can result from bleeding anywhere in the urinary tract. Rarely, hematuria is a sign of clinically significant renal disease. Microscopic hematuria in patients less than 40 years of age is almost always benign, and further work-up is rarely indicated. Occasionally, significant underlying disease such as a neoplasm or proliferative glomerulonephritis can cause hematuria. However, the accompanying active sediment of proteins and red blood cell casts makes the diagnosis relatively straightforward. In older people, hematuria warrants further evaluation, including urologic studies to rule out prostatic hypertrophy and neoplasia, urine cultures to rule out infection, urine cytology, and advanced renal studies (such as an intravenous pyelography) to rule out intrinsic abnormalities. Proteinuria is probably the most sensitive sign of renal dysfunction. However, many benign conditions (including, exercise, stress, and fever) can produce elevated protein in the urine, or the proteinuria may be idiopathic. A 24-hour urine collection should be done for persistent proteinuria. The upper limit of normal urinary protein is 150 mg per day; patients who excrete > 3g of protein per day carry a diagnosis of nephrotic syndrome (discussed below).
Specific gravity is measured to determine the concentration of urine. In chronic renal disease, the kidney initially loses its ability to concentrate the urine, then loses its abilty to dilute the urine, resulting in a relatively fixed osmolality near the specific gravity of plasma. This occurs when 80% of the nephron mass has been destroyed.
Creatinine Clearance Test
The glomerular filtration rate assesses the amount of functioning renal tissue and can be calculated indirectly by the endogenous creatinine clearance test. Creatinine is a breakdown product of muscle, liberated from muscle tissue and excreted from the urine at a constant rate. This results in a steady plasma concentration of 0.7 to 1.5 mg/dL (often slightly higher in men because of increased muscle mass). Creatinine is 100% filtered by the glomerulus and is not reabsorbed by the tubule. Although a very small portion is secreted by the tubule, this test is an effective way to estimate the GFR. The creatinine clearance test is performed by collecting a 24-hour urine specimen and a blood sample in the same 24-hour period. In chronic renal failure and in some forms of acute disease, the GFR is decreased below the normal range of 100 to 150 mL/min. Advancing age also diminishes the GFR, by approximately 1 mL/min every year after age 30 years. The most accurate way to measure the GFR is by the inulin clearance test. However, this clinical test is infrequently used because it requires intravenous infusion at a constant rate and timed urine collection by catheterization.
Intravenous Pyelography
Intravenous pyelography (IVP) is the most commonly used and relied upon radiologic examination of the kidneys. Following the intravenous (IV) injection of a contrast medium, a plain-film abdominal radiograph is taken. Further films are exposed every minute for the first 5 minutes, followed by a film exposed at 15 minutes and a final film exposed at 45 minutes. Since various diseases of the kidney alter its ability to concentrate and excrete the dye, the extent of renal damage can be assessed. The location and distribution of the dye itself gives information regarding the position, size, and shape of the kidneys. This examination has limited application, particularly since in severely azotemic patients (whose BUN > 70 mg/dL), this test is deferred because there is sufficiently low glomerular filtration to prevent the excretion of the dye, rendering information about the kidney nondiagnostic.
Renal Ultrasonography
Ultrasonography of the kidneys finds its usefulness in the enhanced ability to distinguish solid tumors from fluid-filled cysts. 1 This diagnostic procedure uses high-frequency sound waves (ultrasound) directed at the kidneys to produce reflected waves or echoes from tissues of varying densities, thereby forming images (sonograms). Renal ultrasonography is particularly useful for patients with severe renal failure who are not candidates for IVP. It is most often indicated to determine kidney size, to view an obstruction, to evaluate renal transplants for abscesses or hematomas, and to localize the organ during percutaneous renal biopsy.
Computed Tomography and Magnetic Resonance Imaging
Computed tomography (CT) and magnetic resonance imaging (MRI) have limited application for imaging the kidney and associated areas of interest. Because CT is more expensive than conventional radiographic studies, its clinical application has been limited to the detection of retroperitoneal masses that are difficult to detect with other modalities. MRI gives the same information as renal CT but does not use ionizing radiation or require intravenous contrast media.
Biopsy
The development and growing use of renal biopsy has considerably advanced the knowledge of the natural history of kidney diseases. Percutaneous needle biopsy guided by ultra- 
▼ RENAL FAILURE
The classification of renal failure is based on two criteria: the onset (acute versus chronic failure) and the location that precipitates nephron destruction (prerenal, renal or instrinsic, and postrenal failure). Chronic renal failure is a slow, irreversible, and progressive process that occurs over a period of years whereas acute renal failure develops over a period of days or weeks. The distinction between acute and chronic disease is important; acute disease is usually reversible if managed appropriately whereas chronic renal failure is a progressive and irreversible process that leads to death in the absence of medical intervention. In both cases, the kidneys lose their normal ability to maintain the normal composition and volume of bodily fluids. Although the terminal functional disabilities of the acute and chronic diseases are similar, acute renal failure has some unique aspects that warrant its separate discussion.
Acute Renal Failure
Acute renal failure (ARF) is a clinical syndrome characterized by a rapid decline in kidney function over a period of days to weeks, leading to severe azotemia (the building up of nitrogenous waste products in the blood). It is very common in hospitalized patients; ARF occurs in up to 5% of all admitted patients and in as many as 30% of patients admitted to intensive care units. Medications, surgery, pregnancy-related complications, and trauma are the most common causes of ARF. Unlike patients who undergo chronic renal failure, patients who develop ARF usually have a normal baseline renal function; yet, mortality from ARF (even with medical intervention including dialysis) can reach 80%, demonstrating the critical illness of these patients. 2 The clinical course of acute renal failure most often progresses through three stages: oliguria (urine volume < 400 mL per day), diuresis (high urine volume output > 400 mL per day), and ultimately, recovery. 3 The causes of ARF are often divided into three diagnostic categories: prerenal failure, postrenal failure, and acute intrinsic renal failure.
PRERENAL FAILURE
Prerenal failure, defined as any condition that compromises renal function without permanent physical injury to the kidney, is the most common cause of hospital-acquired renal failure. This condition, often referred to as prerenal azotemia, results from reversible changes in renal blood flow and is the most common cause of acute renal failure, accounting for more than 50% of cases. 4 Some etiologic factors commonly associated with prerenal failure include volume depletion, cardiovascular diseases that result in diminished cardiac output, and changes in fluid volume distribution that are associated with sepsis and burns. 5 
POSTRENAL FAILURE
Postrenal causes of failure are less common (< 5% of patients) than prerenal causes. Postrenal failure refers to conditions that obstruct the flow of urine from the kidneys at any level of the urinary tract and that subsequently decrease the GFR. Postrenal failure can cause almost total anuria with complete obstruction or polyuria. Renal ultrasonography often shows a dilated collecting system (hydronephrosis). Most commonly, obstruction results from prostatic enlargement (benign hypertrophy or malignant neoplasia) or cervical cancer. It is usually seen in older men as a result of the enlargement of the prostate gland. Although postrenal failure is the least common cause of acute renal failure, it remains the most treatable.
ACUTE INTRINSIC RENAL FAILURE
Glomerular disease, vascular disease, and tubulointerstitial disease comprise the three major causes of acute intrinsic renal failure and describe the sites of pathology. Glomerulonephritis is an uncommon cause of acute renal failure and usually follows a more subacute or chronic course. However, when fulminant enough to cause acute failure, it is associated with active urinary sediment. Prominent clinical and laboratory findings include hypertension, proteinuria, hematuria, and red blood cell casts. Postinfectious, membranoproliferative, and rapidly progressive glomerulonephritis, as well as glomerulonephritis associated with endocarditis and infections of the vascular access, are the most common glomerular diseases to cause a sudden renal deterioration. The pathogenesis of glomerulonephritis appears to be related to the immunocomplex and complement-mediated damage of the kidney. 6 Vascular occlusive processes such as renial arterial or venous thromboses are also causes of acute intrinsic renal failure. The clinical presentation is archetypal, consisting of a triad of severe and sudden lower back pain, severe oliguria, and macroscopic hematuria. By far, the most common causes of acute intrinsic failure are tubulointerstitial disorders (> 75% of cases), including interstitial nephritis and acute tubular necrosis (ATN). Infiltrative diseases (such as lymphoma or sarcoidosis), infections (such as syphilis and toxoplasmosis), and medications are the leading causes of interstitial nephritis. With drug-induced interstitial nephritis, there are accompanying systemic signs of a hypersensitivity reaction, and the presence of eosinophils is a common finding in the urine. Although renal function returns to normal with the discontinuation of the offending drug, recovery may be hastened with corticosteroid therapy. 7 ATN is a renal lesion that forms in response to prolonged ischemia or exposure to a nephrotoxin. 8 ATN remains more of a clinical diagnosis of exclusion than a pathologic diagnosis. The period of renal failure associated with ATN can range from weeks to months, and the major complications of this transient failure are infections, imbalances in fluid and electrolytes, and uremia. Serum levels of BUN and creatinine peak, plateau, and slowly fall, accompanied by a return of renal function over 10 to 14 days in most cases. 9 Sudden renal failure in hospitalized patients is often very apparent from either oliguria or a rise in BUN and creatinine levels. However, renal dysfunction in the outpatient population is often more subtle. A patient can present to the dental office with vague complaints of lethargy and fatigue or entirely without symptoms. These patients can often go undiagnosed but for abnormal results on routine urinalysis, the most common test for screening for renal disease. 10, 11 Chronic Renal Failure Chronic renal failure (CRF) can be caused by many diseases that devastate the nephron mass of the kidneys. Most of these conditions involve diffuse bilateral destruction of the renal parenchyma. Some renal conditions affect the glomerulus (glomerulonephritis), others involve the renal tubules (polycystic kidney disease or pyelonephritis), while others interfere with blood perfusion to the renal parenchyma (nephrosclerosis). Ultimately, nephron destruction ensues in all cases unless this process is interrupted. The United States Renal Data System has generated statistics showing that the most common primary diagnosis for CRF or end-stage renal disease (ESRD) patients is diabetes mellitus, followed by hypertension, glomerulonephritis, and others (Table 15-3) . Despite the varying causes, the clinical features of CRF are always remarkably similar because the common denominator remains nephron destruction.
The prognosis of the patient with renal disease has improved significantly during the last two decades. The improvement of antimicrobial therapy to combat increased susceptibility to infection, along with advances in dialysis and transplantation techniques, has provided patients with the opportunity for survival in the face of a complete loss of renal function. However, despite these advances, the current annual mortality rate for patients with ESRD in the United States is approximately 24%.
CLINICAL PROGRESSION
The clinical course of CRF is divided into three progressive stages: (1) diminished renal reserve, (2) renal insufficiency, and (3) end-stage renal failure or uremia.
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Diminished renal reserve is characterized by normal serum creatinine and BUN levels. There are no symptoms or prominent biochemical disturbances. Renal impairment may be detected only when severe demands are being placed on the kidneys or by sophisticated testing of the GFR. The second clinical stage, renal insufficiency, occurs when the GFR drops to 25% of normal (> 75% of functional kidney tissue has then been destroyed). As nephron destruction progresses, the GFR falls, and the BUN level rises. Among the consequences are (usually) mild azotemia, nocturia, polyuria, and an impaired ability to concentrate urine. The third and final stage of chronic renal failure is end-stage renal failure or uremia. With continued destruction of nephrons (destruction of > 90% of nephron mass), frank renal disease follows, with associated polyuria. The GFR is 10% of normal, and creatinine clearance may be 5 to 10 mL/min or less. Sharp increases in serum creatinine and BUN are seen in response to small decrements in the GFR. At this point, patients experience severe symptoms as their kidneys cannot maintain fluid and electrolyte homeostasis. The complex biochemical changes, including anemia, hypocalcemia, hyperphosphatemia, and metabolic acidosis, along with vast systemic symptoms, a patient experiences, has been termed "uremic syndrome." Without renal replacement therapy, death is a certain consequence. 12 
ETIOLOGY AND PATHOGENESIS
The progression of the varied renal diseases, culminating in chronic renal failure, ranges from a few months to 30 to 40 years. The most common causes of renal failure are summarized in Table 15 -3. Currently, diabetes and hypertension account for 44.4% and 26.6%, respectively, of the total cases of ESRD. Glomerulonephritis is the third most common cause of ESRD (12.2% of cases). Interstitial nephritis, pyelonephritis, and polycystic kidney disease account for 7.2% of cases. The remaining 9.6% of the causes of ESRD include systemic lupus erythematosus (SLE) and relatively uncommon conditions such as obstructive uropathy.
Age, race, gender, and family history have been identified as risk factors for the development of ESRD. 13 The average age of a newly diagnosed patient with ESRD is 61.1 years, and 53.1% of ESRD patients are male. White people, including Hispanics, account for 63.5% of ESRD patients; black people account for 28.7% of ESRD patients, and people of Asian ancestry make up 2.9%. Family history is a risk factor for diabetes and hypertension, both of which adversely affect the kidneys and therefore constitute a risk for developing ESRD. Recent evidence suggests that smoking is a major renal risk factor, increasing the risk of nephropathy and doubling the rate of progression to end-stage disease. 14 Glomerulonephritis. Glomerulonephritis represents a heterogeneous group of diseases of varying etiology and pathogenesis that produce irreversible impairment of renal function. This is often initiated by an attack of acute glomerulonephritis of streptococcal or nonstreptococcal origin. Glomerulonephritis also may enter the chronic stage from a nephrotic syndrome. The most typical examples of this are idiopathic membranous glomerulonephritis and membranoproliferative glomerulonephritis. 15 In most cases, the patients present with the features of CRF and hypertension or with a chance proteinuria that has progressed to chronic nephritis over a period of years. Chronic glomerulonephritis is usually insidious in onset. The course is very slow but is steadily progressive, leading to renal failure and uremia in up to 30 years. It is thought to be a disorder of immunologic origin. The continuous nature of the immunologic injury is shown by the recurrence of disease in kidneys that have been transplanted to patients with some type of glomerulonephritis, even after their own kidneys had been removed. 16 Nephrotic Syndrome. Nephrotic syndrome is the clinical manifestation of any glomerular lesion that causes an excess of more than 3 g of protein excretion in the urine per day. Nephrotic syndrome is caused by multiple diseases, all of which enhance the permeability of the glomerulus to plasma proteins. Excessive protein excretion leads to a decline of plasma osmotic pressure, with consequent edema and serosal effusions. The differential diagnosis of nephrotic syndrome is vast but includes sickle cell anemia, diabetes mellitus, multiple myeloma, SLE, and membranous glomerulonephritis. Bacterial infections secondary to hypogammaglobulinemia have been described as a cause of death in children with nephrotic syndrome.
Pyelonephritis. Pyelonephritis refers to the effects of bacterial infection in the kidney, with Escherichia coli being the most frequent cause of infection. 17 Pyelonephritis may present in an acute form with active pyogenic infection or in a chronic form in which the principal manifestations are caused by an injury sustained during a preceding infection. The chronic form of bacterial pyelonephritis can be further subdivided into reactive and inactive forms, and one or both kidneys may be affected.
Any lesion that produces an obstruction of the urinary tract can predispose to active pyelonephritis. Pyelonephritis also may occur as part of a generalized sepsis as seen in patients with bacterial endocarditis or staphylococcal septicemia.
The clinical picture of acute pyelonephritis is often characteristic, consisting of a sudden rise in body temperature (to 38.9˚ to 40.6˚C), shaking chills, aching pain in one or both costovertebral areas or flanks, and symptoms of bladder inflammation. Microscopic evaluation of the urine reveals large numbers of bacteria and a polymorphonuclear leukocytosis. There are no signs of impaired renal function or acute hypertension as is sometimes seen in patients with acute glomerulonephritis. Patients with chronic active pyelonephritis often suffer from recurrent episodes of acute pyelonephritis or may have persistent smoldering infections that gradually result in endstage renal failure secondary to destruction from the scarring of renal parenchyma. This process may continue for many years. The inability to conserve sodium (a feature in any patient with impaired renal function) is more pronounced in patients with pyelonephritis than in those with glomerulonephritis. This "salt-losing" defect may be pronounced and may dominate the clinical picture.
Polycystic Renal Disease. Polycystic kidney disease exhibits autosomal dominant inheritance. 18 Most patients present with microscopic or gross hematuria, abdominal or flank pain, and recurrent urinary tract infections. The disease causes renal insufficiency in 50% of individuals by age 70 years. 19 Clinically, these patients have large palpable kidneys, and the diagnosis is confirmed via renal ultrasonography, CT, or IVP. Most patients develop hypertension during the course of their disease, and more than one-half of patients are hypertensive at the time of presentation. Although no preventive therapies have proven to be effective, treating the hypertension with angiotensin-converting enzyme inhibitors may help to slow the progression of polycystic disease. Another form of polycystic kidney disease is an acquired reactive process that is seen in over 50% of patients treated by hemodialysis or peritoneal dialysis for longer than 3 years. The development of adenocarcinomas is seen in approximately 5% of these multiple cysts throughout the remnant kidneys.
Hypertensive Nephrosclerosis. The association between the kidneys and hypertension is recognized, yet the primary disease often is not. Hypertension may be the primary disorder damaging the kidneys, but conversely, severe chronic renal failure may lead to hypertension or perpetuate it through changes in sodium and water excretion and/or in the reninangiotensin system. 20 Hypertension remains one of the leading causes of chronic renal failure, especially in nonwhite populations. (See Chapter 13, "Diseases of the Cardiovascular System," for detailed discussion of hypertension.) The heart, brain, eyes, and kidneys comprise the four major target organs of hypertension. Long-standing hypertension leads to fibrosis and sclerosis of the arterioles in these organs and throughout the body. Benign nephrosclerosis results from arteriosclerotic changes due to long-standing hypertension. It is the direct result of ischemia caused by narrowing of the lumina of the intrarenal vascular supply. The progressive closing of the arteries and arterioles leads to atrophy of the tubules and destruction of the glomerulus. "Malignant nephrosclerosis" refers to the structural changes that are associated with the malignant phase of essential hypertension.
Connective-Tissue Disorders. Renal diseases are very prevalent among patients with connective-tissue disorders, commonly referred to as collagen vascular diseases. Approximately two-thirds of patients with SLE and scleroderma or progressive systemic sclerosis (PSS) have clinical evidence of renal involvement. In rheumatoid arthritis, the prevalence of renal involvement is considerably less and is often related to complications of treatment with gold salts or D-penicillamine).
End-stage renal failure occurs in 25% of patients with SLE. Lupus nephritis, caused by circulating immunocomplexes that become trapped in the glomerular basement membrane, produces a clinical picture similar to that of acute glomerular nephritis or nephrotic syndrome. 21 PSS is characterized by the progressive sclerosis of the skin and viscera, including the kidneys and their vasculature, leading to changes resembling the nephrosclerosis seen in patients with long-standing hypertension.
Metabolic Disorders. The most common metabolic disorders that may lead to CRF include diabetes mellitus (DM), amyloidosis, gout, and primary hyperparathyroidism. By far, diabetes mellitus is one of the most important causes of CRF and accounts for nearly one-half of new ESRD patients (data from US Renal Data System, 1999). The type of diabetes the patient has affects the probability that the patient will develop ESRD. It has been estimated that about 50% of patients with type 1 DM develop ESRD within 15 to 25 years after the onset of diabetes, compared to 6% for patients with type 2 DM. The term "diabetic nephropathy" refers to the various changes that affect the structure and function of the kidneys in the presence of diabetes. Glomerulosclerosis is the most characteristic lesion of diabetic nephropathy. Other lesions include chronic tubulointerstitial nephritis, papillary necrosis, and ischemia. The natural progression of diabetic nephropathy follows five stages, beginning with early functional changes (stage 1) and progressing through early structural changes (stage 2), incipient nephropathy (stage 3), clinical diabetic nephropathy (stage 4), and finally, progressive renal insufficiency or failure (stage 5). The final stage is characterized by azotemia (elevated BUN and serum creatinine) resulting from a rapid decline in the GFR and leading to ESRD.
Toxic Nephropathy. The kidney is particularly exposed to the toxic effects of chemicals and drugs because it is an obligatory route of excretion for most drugs and because of its large vascular perfusion. 22 There are medications and other agents (referred to as "classic" nephrotoxins) whose use leads directly to renal failure. However, abuse of nonsteroidal anti-inflammatory drugs (NSAIDs) can also result in CRF. The renal protective effects of prostaglandins are inhibited by NSAIDs. Currently, abuse of analgesics accounts for 1 to 2% of all ESRD cases in the United States.
▼ MANIFESTATIONS OF RENAL DISEASE: UREMIC SYNDROME
Two groups of symptoms are present in patients with uremic syndrome: symptoms related to altered regulatory and excretory functions (fluid volume, electrolyte abnormalities, acidbase imbalance, accumulation of nitrogenous waste, and anemia) and a group of clinical symptoms affecting the cardiovascular, gastrointestinal, hematologic, and other systems (Table 15-4) . -. These patients often suffer from a moderate acidosis (serum bicarbonate level stabilized at 18 to 20 mEq/L). The symptoms of anorexia, lethargy, and nausea frequently observed in patients with uremia may be due partly to this metabolic acidosis. Kussmaul's breathing, a symptom caused by acidosis, is a deep sighing respiration aimed at increasing carbon dioxide excretion and reducing the metabolic acidosis. Disturbances in potassium balance are serious sequelae of renal dysfunction since only a narrow plasma concentration (normal = 3.5 to 5.5 mEq/L) is compatible with life. Because 90% of the daily intake of potassium is excreted in the urine, hypokalemia is common with the polyuria of early CRF. However, as kidney function continues to deteriorate, hyperkalemia ensues. Fatal dysrythmias or cardiac standstill will occur when the potassium level reaches 7 to 8 mEq/L. The normally functioning kidney allows great flexibility, excreting and conserving sodium in response to changing intake. Patients with CRF lose this adaptability, and small fluctuations often have serious consequences. Initially, patients experience osmotic diuresis and excess sodium excretion because of the polyuria. Sodium loss is more common in those conditions that are likely to affect the tubules (polycystic kidney disease and pyelonephritis). When oliguria develops in endstage renal failure, sodium retention invariably occurs, resulting in edema, hypertension, and congestive heart failure.
Gastrointestinal Symptoms
The gastrointestinal system, particularly the esophagus, stomach, duodenum, and pancreas, show a myriad of symptoms in cases of uremic syndrome. The more common symptoms are often the first signs of the disease and include nausea, vomiting, and anorexia. Gastrointestinal inflammations such as gastritis, duodenitis, and esophagitis are common in late renal failure and can affect the entire gastrointestinal tract. Mucosal ulceration in the stomach, small intestine, and large intestine may hemmorhage, resulting in lowered blood pressure and a resultant lowered GFR. Digestion of hemorrhagic blood may lead to a rapid increase in BUN. 23 
Neurologic Signs and Symptoms
Some of the early signs and symptoms of CRF are related to changes in the neurologic system. 24 Both central and peripheral nervous systems are involved, with diverse consequences. The degree of cerebral disturbance roughly parallels the degree of azotemia. The patient's electroencephalogram becomes abnormal, with changes that are commensurate with metabolic encephalopathy. As the disease progresses, asterixis and myoclonic jerks may become evident; central nervous system irritability and eventual seizures may occur. Seizures also can occur secondary to hypertensive encephalopathy, electrolyte disturbances (such as hyponatremia), and alkalosis, which induces hypocalcemia.
Along with neurologic hyperirritability, peripheral neuropathy is commonly present as a result of a disturbance of the conduction mechanism rather than a quantitative loss of nerve fiber. The clinical picture is dominated by sensory symptoms and signs. Impairment of vibratory sense and loss of deep tendon reflexes are the earliest, most frequent, and most constant findings. The predominant patient complaint is paresthesia or "burning feet" that may progress to eventual muscle weakness, atrophy, and finally, paralysis; there is a tendency toward increasing incidence with decreasing renal function. This predominantly affects the lower extremities but can affect the upper extremities as well. Rarely, facial, oral, and paraoral regions also can be affected. Severe uremic neuropathy is less commonly seen today because dialysis or transplantation is usually performed before uremic symptoms become prolonged or severe. Renal replacement therapy may halt the progress of peripheral neuropathy, but once these changes occur, sensory changes are poorly reversible while motor changes are considered irreversible.
The treatment of renal failure also may lead to the development of neurologic abnormalities in the form of dialysis disequilibrium, often seen during the first or second dialysis treatments and characterized by headache, nausea, and irritability that can progress to seizures, coma, and death.
Hematologic Problems
Patients with chronic renal dysfunction will often have hematologic problems, most commonly anemia and increased bleeding. The anemia associated with renal disease is a function of decreased erythropoiesis in the bone marrow and is usually normocytic and normochromic. It is not uncommon for these patients to have hematocrit levels in the 20 to 35% range (normal levels are 42 to 54% in males and 37 to 47% in females). The pathogenesis of the anemia is multifactorial, with nutritional deficiencies, iron metabolism abnormalities, and circulating uremic toxins that inhibit erythropoiesis all playing a role. The major factor, however, is the inability of the diseased kidney to produce erythropoietin, which stimulates (through a feedback mechanism) the bone marrow to produce red blood cells. Hypertension, retention of waste products, and altered body fluid pH and electrolyte composition create a suboptimal environment for living cells; therefore, an accelerated destruction of red blood cells contributes to the anemia. Another cause of anemia in many dialysis patients is the frequent blood sampling and loss of blood in hemodialysis tubing and coils.
These patients may also have a microcytic hypochromic anemia that is usually caused by aluminum ion overload or deficiencies in iron stores. The former occurs from aluminumcontaining medications, often given as phosphate-binding agents to control hyperphosphatemia. Aluminum also can be found in domestic tap water supplies or in nondealuminized dialysis water. This form of anemia is treated by chelation with desferoxamine. 25 Interestingly, these patients tolerate their anemia quite well. Whole-blood transfusions are usually unnecessary, with the exception of cases of significant surgical blood loss or when the patient exhibits severe symptoms of anemia. These symptoms and signs of anemia may include pallor, tachycardia, systolic ejection murmur, a widened pulse pressure, and angina pectoris (in patients with underlying coronary artery disease). Transfusions may further suppress the production of red blood cells. The risk of hepatitis B and C, human immunodeficiency virus (HIV) infection, and other bloodborne infections is increased with the number of transfusions although blood screening techniques continue to minimize these risks.
Recombinant human erythropoietin (epoetin alfa [Epogen, Procrit]) corrects the anemia of ESRD and eliminates the need for transfusions in virtually all patients. 26 A dosage of 50 to 150 U/kg of body weight IV three times a week produces an increase in hematocrit of approximately 0.01 to 0.02 per day. [27] [28] [29] During early therapy, iron deficiency will develop in most patients. It is therefore initially essential to monitor the body's iron stores monthly. 30 With all patients, except those with transfusional iron overloads, prophylactic supplementation with ferrous sulfate (325 mg up to three times daily) is recommended. 31, 32 Onset or exacerbation of hypertension has been observed as a possible complication of recombinant human erythropoietin therapy for the anemia of ESRD. 33 This effect is attributed to an overly rapid rise in the hematocrit level in the accompanying increased hemoglobin, blood viscosity, and renal cell mass. 34 Bleeding may be a significant problem in patients with end-stage renal failure, and it has been attributed to increased prostacycline activity, increased capillary fragility, and a deficiency in platelet factor 3. The bleeding risk in renal failure results from an acquired qualitative platelet defect secondary to uremic toxins that decrease platelet adhesiveness. In addition, the low hematocrit levels commonly found in uremic patients negatively influence the rheologic component of platelet-vessel wall interactions. Platelet defects secondary to uremia is best remedied by dialysis but is also treated successfully by cryoprecipitate or l-deamino-8-D-arginine vasopressin (DDAVP). 35 Platelet numbers affect bleeding, and mechanical trauma to the platelets during dialysis can cause a decrease of up to 17% in the platelet count. In addition to lowered platelet counts (which are usually not clinically significant) and qualitative platelet defects, the effects of medications on platelets contribute to bleeding episodes.
During dialysis, patients are given heparin to facilitate blood exchange and to maintain access patency. However, since the effects of heparinization during dialysis last only approximately 3 to 4 hours after infusion, the risk of excessive clinical bleeding because of anticoagulation is minimal in dentistry. 36 Some patients have a tendency to be hypercoagulable; for these patients, a regimen of warfarin sodium (Coumadin) therapy may be instituted to maintain a continuous anticoagulated state and to ensure shunt patency.
Calcium and Skeletal Disorders (Renal Osteodystrophy)
"Renal osteodystrophy" refers to the skeletal changes that result from chronic renal disease and that are caused by disorders in calcium and phosphorus metabolism, abnormal vitamin D metabolism, and increased parathyroid activity. In early renal failure, intestinal absorption of calcium is reduced because the kidneys are unable to convert vitamin D into its active form. Upon exposure to sunlight, 7-dehydroxycholesterol in the skin is converted to cholecalciferol (vitamin D 3 ) and is subsequently metabolized in the liver to a more biologically active form, 25-hydroxycholecalciferol (25-HCC). Further conversion to either 1,25-dihydroxycholecalciferol (1,25-DHCC) or 21,25-dihydroxycholecalciferol (21,25-DHCC) then occurs in the kidney parenchyma.
When the serum calcium level is high, 25-HCC is metabolized to 21,25-DHCC; conversely, a hypocalcemic state initiates the conversion of 25-HCC to 1,25-DHCC. This form is the most biologically active for absorbing calcium from the digestive tract. Impaired absorption of calcium because of defective kidney function and the corresponding retention of phosphate cause a decrease in the serum calcium level. This hypocalcemia is associated with a compensatory hyperactivity of the parathyroid glands (parathyroid hormone production) that increases the urinary excretion of phosphates,
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Principles of Medicine decreases urinary calcium excretion, and augments the release of calcium from bone. The most frequently observed changes associated with compensatory hyperparathyroidism (HPTH) are those that involve the skeletal system. These changes can appear before and during treatment with hemodialysis. Although it is a lifesaving therapy, hemodialysis unfortunately fails to perform vital metabolic or endocrine functions and does not correct the crucial calcium-phosphate imbalance. In some cases, renal osteodystrophy becomes worse during hemodialysis. Some of the changes that are accelerated are bone remodeling, osteomalacia, osteitis fibrosa cystica (a rarefying osteitis with fibrous degeneration and cystic spaces that result from hyperfunction of the parathyroid glands), and osteosclerosis. 37 The bone lesions are usually in the digits, the clavicle, and the acromioclavicular joint. Other lesions that can be seen are mottling of the skull, erosion of the distal clavicle and margins of the symphysis pubis, rib fractures, and necrosis of the femoral head. 38 The manifestations of metabolic renal osteodystrophy of the jaws include bone demineralization, decreased trabeculation, a "ground-glass" appearance, loss of lamina dura, radiolucent giant cell lesions, and metastatic soft-tissue calcifications.
In children, the predominant lesion is osteomalacia (a deficiency or absence of osteoid mineralization), which is associated with bone softening that leads to deformities of the ribs, pelvis, and femoral neck (renal rickets). Early stages of renal osteodystrophy may be detected histologically or biochemically without the presence of definitive radiographic changes because dependable radiographic evidence of bone disease appears only after 30% of bone mineral contents have been lost.
Osteodystrophy patients are placed on protein-restricted diets and phosphate binders (calcium carbonate or calcium acetate) to keep the serum phosphorus within the normal range (between 3.5 and 5.0 mg/dL). They also are given vitamin D supplements (such as 1,25-DHCC). If these measures fail, a parathyroidectomy may be performed, whereby two or more of the four glands are removed, leaving residual parathyroid hormone-secreting tissue. 39 Most recently, a new form of renal bone disease termed adynamic bone disease has emerged as the most frequent finding on bone biopsy of patients who are on dialysis. The etiology of this new condition is not fully understood, but relatively low levels of intact serum parathyroid hormone are often associated with this disorder and may play a role in its pathogenesis. 40 
Cardiovascular Manifestations
Hypertension and congestive heart failure are common manifestations of uremic syndrome. Alterations in sodium and water retention account for 90% of cases of hypertension in CRF patients. 41 The association of circulatory overload and hypertension caused by disturbances in sodium and water balance contributes to an increased prevalence of congestive heart failure. In addition, retinopathy and encephalopathy can result from severe hypertension. Because of the early initiation of dialysis, the once frequent complication of pericarditis resulting from metabolic cardiotoxins is rarely seen. 42 
Respiratory Symptoms
Kussmaul's respirations (the deep sighing breathing seen in response to metabolic acidosis) is seen with uremia. Initially, however, dyspnea on exertion is a more frequent and often overlooked complaint in patients with progressing disease. The other respiratory complications, pneumonitis and "uremic lung," result from pulmonary edema associated with fluid and sodium retention and/or congestive heart failure.
Immunologic Changes
The significant morbidity experienced by patients with renal failure can be attributed to their altered host defenses. Uremic patients appear to be in a state of reduced immunocapacity, the cause of which is thought to be a combination of uremic toxemia and ensuing protein and caloric malnutrition compounded by protein-restricted diets. Uremic plasma contains nondialyzable factors that suppress lymphocyte responses that are manifested at the cellular and humoral levels, such as granulocyte dysfunction, suppressed cell-mediated immunity, and diminished ability to produce antibodies. 43 In addition, impaired or disrupted mucocutaneous barriers decrease protection from environmental pathogens. Together, these impairments place uremic patients at a high risk of infection, which is a common cause of morbidity and mortality.
Oral Manifestations
With impaired renal function, a decreased GFR, and the accumulation and retention of various products of renal failure, the oral cavity may show a variety of changes as the body progresses through an azotemic to a uremic state (Table 15-5 ). The general dentist should be able to recognize these oral symptoms as part of the patient's systemic disease and not as an isolated occurrence. In studies of renal patients, up to 90% were found to have oral symptoms of uremia. Some of the presenting signs were an ammonia-like taste and smell, stomatitis, gingivitis, decreased salivary flow, xerostomia, and parotitis.
As renal failure develops, one of the early symptoms may be a bad taste and odor in the mouth, particularly in the morning. This uremic fetor, an ammoniacal odor, is typical of any uremic patient and is caused by the high concentration of urea in the saliva and its subsequent breakdown to ammonia. Salivary urea levels correlate well with the BUN levels, but no fixed linear relationship exists. An acute rise in the BUN level may result in uremic stomatitis, which may appear as an erythemopultaceous form characterized by red mucosa covered with a thick exudate and a pseudomembrane or as an ulcerative form characterized by frank ulcerations with redness and a pultaceous coat. In all reported cases, intraoral changes have been related to BUN levels > 150 mg/dL and disappear spontaneously when medical treatment results in a lowered BUN level. Although its exact cause is uncertain, uremic stomatitis can be regarded as a chemical burn or as a general loss of tissue resistance and inability to withstand normal and traumatic influences. White plaques called "uremic frost" and occasionally found on the skin can rarely be found intraorally. This uremic frost results from residual urea crystals left on the epithelial surfaces after perspiration evaporates or as a result of decreased salivary flow. A more common oral finding is significant xerostomia, probably caused by a combination of direct involvement of the salivary glands, chemical inflammation, dehydration, and mouth breathing (Kussmaul's respiration). Salivary adenitis can occasionally be seen. Another finding associated with increased salivary urea nitrogen, particularly in children, is a low caries activity. This is observed despite a high sugar intake and poor oral hygiene, suggesting an increased neutralizing capacity of the urea arising from ureal hydrolysis. With the increased availability and improved techniques of dialysis and transplantation, many of the oral manifestations of uremia and renal failure are less commonly observed.
Other oral manifestations of renal disease are related to renal osteodystrophy (RO) or secondary HPTH. These manifestations usually become evident late in the course of the disease. The classic signs of RO in the mandible and maxilla are bone demineralization, loss of trabeculation, ground-glass appearance, total or partial loss of lamina dura, giant cell lesions or brown tumors, and metastatic calcifications ( Figure  15-2) . These changes appear most frequently in the mandibular molar region superior to the mandibular canal. The rar- efaction in the mandible and maxilla is secondary to generalized osteoporosis. The finer trabeculae disappear later, leaving a coarser pattern. Small lytic lesions that histologically prove to be giant cell or brown tumors may occur. The compact bone of the jaws may become thinned and eventually disappear. This may be evident as loss of the lower border of the mandible, the cortical margins of the inferior dental canal and floor of the antrum, and lamina dura. Studies have shown that the finding of decreasing thickness of cortical bone at the angle of the mandible correlates well with the degree of RO. Spontaneous and pathologic fractures may occur with the thinning of these areas of compact bone and may complicate dental extractions.
While the skeleton may undergo decalcification, fully developed teeth are not directly affected; however, in the presence of significant skeletal decalcification, the teeth will appear more radiopaque. The loss of lamina dura is neither pathognomonic for nor a consistent sign of HPTH. A similar loss of lamina dura also may be seen in Paget's disease, osteomalacia, fibrous dysplasia, sprue, and Cushing's and Addison's diseases. Various studies indicate changes in lamina dura in only 40 to 50% of known HPTH patients.
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The radiolucent lesions of HPTH are called "brown tumors" because they contain areas of old hemorrhage and appear brown on clinical inspection. As these tumors increase in size, the resultant expansion may involve the cortex. Although the tumor rarely breaks through the periosteum, gingival swelling may occur. The brown tumor lesion contains an abundance of multinucleated giant cells, fibroblasts, and hemosiderin. This histologic appearance is also consistent with central giant cell tumor and giant cell reparative granuloma. Associated bone changes consist of a generalized osteitis fibrosa, with patches of osteoclastic resorption on all bone surfaces. This is replaced by a vascular connective tissue that represents an abortive formation of coarse-fibered woven bone. This histologic picture also may be seen in fibrous dysplasia, giant cell reparative granuloma, osteomalacia, and Paget's disease.
Other clinical manifestations of RO include tooth mobility, malocclusion, and metastatic soft-tissue calcifications. Increasing mobility and drifting of teeth with no apparent pathologic periodontal pocket formation may be seen. Periapical radiolucencies and root resorption also may be associated with this gradual loosening of the dentition. The teeth may be painful to percussion and mastication, and positive thermal and electric pulp test responses often will be elicited. Splinting is a useful adjunct to prevent pain and further drifting, and the splint should be maintained until adequate treatment of the HPTH results in bone remineralization. Malocclusion may result from the advanced mobility and drifting of the dentition. Extreme demineralization and collapse of the temporomandibular and paratemporomandibular bones may also produce a malocclusion.
Metastatic calcification can occur, particularly when the calcium-phosphate solubility product (Ca × P) is > 70. In normal subjects, a relationship exists between plasma calcium and inorganic phosphate. When expressed in terms of total calcium and inorganic phosphate (both as milligrams per deciliter), the ion product or calcium-phosphate solubility product (Ca × P) is normally an average of 35. A rise in the calcium-phosphate ion product in the extracellular fluid may cause metastatic calcifications because of the precipitation of calcium phosphate crystals into the soft tissues, such as the sclera, corner of the eye, subcutaneous tissue, skeletal and cardiac muscle, and blood vessels. This also may occur in the oral and associated paraoral soft tissues. These calcifications are often visible radiographically.
Abnormal bone repair after extraction, termed "socket sclerosis" and radiographically characterized by a lack of lamina dura resorption and by the deposition of sclerotic bone in the confines of the lamina dura, has been reported in patients with renal disease although it is not unique to them (Figure 15-3) .
Enamel hypoplasia (a white or brownish discoloration) is frequently seen in patients whose renal disease started at a young age. The location of the hypoplastic enamel on the permanent teeth corresponds to the age of onset of advanced renal failure. Prolonged corticosteroid administration also may contribute to this deficiency ( Figure 15-4) . Another frequent dental finding is pulpal narrowing and calcifications. In some patients who are on dialysis, severe tooth erosion as a result of the nausea and extensive vomiting that often follows dialysis treatment may be seen. Because of the platelet changes with renal disease itself and with dialysis therapy, gingival bleeding may be a common patient complaint.
▼ MEDICAL MANAGEMENT OF CHRONIC RENAL FAILURE
The treatment of CRF is often divided into (1) conservative therapy aimed at delaying progressive renal dysfunction and (2) renal replacement therapy, instituted when conservative measures are no longer effective in sustaining life.
Conservative Therapy
Once the extent of renal impairment is established and reversible causes are excluded, medical management is devoted to the elimination of symptoms and the prevention of further deterioration. 44 Conservative measures are initiated when the patient becomes azotemic. Initial conservative therapy is directed towards managing diet, fluid, electrolytes, and calcium-phosphate balance and toward the prevention and treatment of complications. 45 Dietary modifications are initiated with the onset of uremic symptoms. Dietary regulation of protein (20 to 40 g per day) may improve acidosis, azotemia, and nausea. The restriction of protein not only reduces BUN levels but reduces potassium and phosphate intake and hydrogen ion production. Also, a low-protein intake reduces the excretory load of the kidney, thereby reducing glomerular hyperfiltration, intraglomerular pressure, and secondary injury of nephrons. 46, 47 This restricted diet is often supplemented with multivitamins specific to the needs of the renal patient. Despite difficulties with hypertension, edema, and weight gain, salt and fluid excess and depletion must be avoided. For patients with early renal insufficiency, prevention of hyperphosphatemia by limiting the intake of phosphate-containing foods and by supplementing the diet with calcium carbonate (which prevents intestinal absorption) may potentially minimize the sequelae of uremic osteodystrophy. 48 Recently, a practical clinical approach to the management of patients with CRF, using the acronym BEANS, has gained popularity. To temper renal dysfunction, attenuate uremic complications, and prepare patients for renal replacement therapy, medical care providers should "take care of the BEANS," as follows. 49 Blood pressure should be maintained in a target range lower than 130/85 mm Hg. (Toward this end, the use of angiotensin-converting enzyme inhibitors, because of their renal protective effects, has gained favor with many clin-icians.) Hemoglobin levels should be maintained at 10 to 12 g/dL with Erythropoietin. Access for dialysis should be created when the serum creatinine reaches > 4.0 mg/dL or the GFR falls to < 20 mL/min. Close monitoring of Nutritional status is important to avoid protein malnutrition, correct metabolic acidosis, prevent and treat hyperphosphatemia, administer vitamin supplements, and guide the initiatiation of dialysis therapy. Specialty evaluation by a nephrologist should be instituted when serum creatinine is > 3.0 mg/dL.
Renal Replacement Therapy
For patients with ESRD, dialysis has significantly decreased the mortality of this once invariably fatal disease. Long-term maintenance dialysis therapy has been a reality since 1961. In 1964, there were fewer than 300 patients in the United States receiving dialysis. Because of amendments to the Social Security Act in 1972 and the extension of Medicare benefits in 1973, dialysis therapy was made available to virtually everybody who developed ESRD. Although access to treatment is of less concern today, discrepancies between the morbidity and mortality rates of for-profit and not-for-profit dialysis centers remain a source of controversy. 50, 51 Today, approximately 260,000 people are given treatments in more than 3,000 dialysis facilities in the United States.
There are no clear guidelines for determining when renal replacement therapy should begin. Most nephrologists base their decisions on the individual patient's ability to work fulltime, the presence of peripheral neuropathy, and the presence of other signs of clinical deterioration. Serum creatinine levels of > 6 mg/dL in males (4 mg/dL in females) and a GFR < 4 mL/min are the laboratory thresholds that are often used to indicate the need for dialysis therapy.
There are two major techniques of dialysis: hemodialysis and peritoneal dialysis. Each follows the same basic principle of diffusion of solutes and water from the plasma to the dialysis solution in response to a concentration or pressure gradient.
HEMODIALYSIS
Hemodialysis is the removal of nitrogenous and toxic products of metabolism from the blood by means of a hemodialyzer system. Exchange occurs between the patient's plasma and dialysate (the electrolyte composition of which mimics that of extracellular fluid) across a semipermeable membrane that allows uremic toxins to diffuse out of the plasma while retaining the formed elements and protein composition of blood (Figure 15-5) . Dialysis does not provide the same degree of health as normal renal function provides, because there is no resorptive capability in the dialysis membrane; therefore, valuable nutrients are lost, and potentially toxic molecules are retained. The usual dialysis system consists of a dialyzer, dialysate production unit, roller blood pump, heparin infusion pump, and various devices to monitor the conductivity, temperature, flow rate, and pressure of dialysate and to detect blood leaks and arterial and venous pressures. 52 Dialysis therapy can be delivered to the patient in outpatient dialysis centers, where trained personnel administer ther-
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Principles of Medicine apy on a regular basis, or in the home, where family members trained in dialysis techniques assist the patient in dialysis therapy. It has been shown that patients who undergo dialysis at home fare better psychologically, have a better quality of life, and have lower rates of morbidity and mortality than hospital dialysis patients. 53, 54 Unfortunately, home dialysis may not be applicable for all patients because it is more difficult and requires a high degree of motivation. The frequency and duration of dialysis treatments are related to body size, residual renal function, protein intake, and tolerance to fluid removal. The typical patient undergoes hemodialysis three times per week, with each treatment lasting approximately 3 to 4 hours on standard dialysis units and slightly less time on high-efficiency or high-flux dialysis units. During treatments and for varying amounts of time afterward, anticoagulants are administered by regional or systemic methods.
Vascular access for hemodialysis can be created by a shunt or external cannula system or by an arteriovenous fistula; the fistula is preferred for long-term treatment. The classic construction is a side-to-side anastomosis between the radial artery and the cephalic vein at the forearm. In patients with very thin veins, it can be technically impossible to create a direct arteriovenous fistula, and in some patients, fistulae have clotted in both arms, resulting in a demand for other forms of vascular access (sometimes the thigh is used as a site). A great advance in access capability was the introduction of subcutaneous artificial arteriovenous grafts, beginning with Gore-Tex heterografts (W.L. Gore, Flagstaff, Ariz.). Fistulae are now constructed between arteries and veins by means of saphenous vein, autografts, polytetrafluoroethylene (PTFE) grafts, Dacron, and other prosthetic conduits. Hemodialysis is performed by direct cannulation of these grafts or vascular anastomoses 55, 56 (Figure 15-6 ). There is an increasing trend toward the use of indwelling central venous catheters for maintenance hemodialysis. 57 Despite optimal dialysis, these patients remain chronically ill with hematologic, metabolic, neurologic, and cardiovascular problems that are more or less permanent. Growth alterations may be seen in very young renal disease patients, particularly if they are maintained on hemodialysis. This growth deficiency has been attributed to the poor caloric intake of these patients and to the uremic state. 58 Dietary supplements have produced accelerated growth spurts, and successful kidney transplantation may restore a normal growth rate. 59 The major determining factor is the bone age. For patients older than 12 years of age, it is doubtful that significant growth would be attained.
PERITONEAL DIALYSIS
Peritoneal dialysis accounts for only 10% of dialysis treatments. During peritoneal dialysis, access to the body is achieved via a catheter through the abdominal wall into the peritoneum. One to two liters of dialysate is placed in the peritoneal cavity and is allowed to remain for varying intervals of time. Substances diffuse across the semipermeable peritoneal membrane into the dialysate. Compared to the membranes used for hemodialysis, the peritoneal membrane has greater permeability for high-molecular-weight species. The Tenckhoff silastic catheter has made peritoneal puncture for each dialysis unnecessary. The Tenckhoff catheter is a permanent intraperitoneal catheter that has two polyester felt cuffs into which tissue growth occurs. If used with a sterile technique, it permits virtually infection-free long-term access to the peritoneum (Figure 15-7) .
Several regimens can be used with peritoneal dialysis. In one, chronic ambulatory peritoneal dialysis (CAPD), 2 L of dialysis fluid is instilled into the peritoneal cavity, allowed to remain for 30 minutes, and then drained out. This is repeated every 8 to 12 hours, 5 to 7 days per week. A popular variation of this is continuous cyclic peritoneal dialysis (CCPD), in which 2 L of dialysate is exchanged every 6 to 8 hours around the clock, 7 days per week. 60 Two of the benefits of peritoneal dialysis are that heparinization is unnecessary and that there is no risk of air embolism and blood leaks. It also allows a great deal of personal freedom; for this reason, is often used as the primary therapy or as a temporary measure. These features, along with its simplicity, make peritoneal dialysis safe for patients who are at risk when hemodialysis is used (eg, the young, elderly patients, those with high-risk coronary and cerebral vascular disease, and those with vascular access problems). 61 Some of the problems encountered with peritoneal dialysis are pain, intra-abdominal hemorrhage, bowel infarction, inadequate drainage, leakage, and peritonitis (approximately 70% of which is caused by a single gram-positive microorganism that is indigenous to the patient's skin or upper respiratory tract and that infects the peritoneal cavity). 62 Today, renal transplantation is the treatment of choice for patients with irreversible kidney failure. However, the use of transplantation is limited by organ availability. (Renal transplantation and its specific dental management considerations are discussed in Chapter ##.)
OTHER APPROACHES TO SOLUTE REMOVAL
Many patients continue to have various disturbances in metabolic functions despite optimal dialysis, maintaining uremic metabolites (eg, urea, creatinine, and phosphate) at nearly normal levels. These observations have led investigators to postulate that uremic toxins of a molecular weight between that of urea (< 500 Da) and that of plasma proteins (> 50,000 Da), effectively unfiltered by dialysis, account for these clinical abnormalities. This theory, termed the middle molecular hypothesis, has led to the development of two techniques: hemofiltration (HF) and absorbent therapy. Hemofiltration is based on the principle of convection instead of diffusion and is based on the physiologic function of the glomerulus. 63 In HF, the standard dialysis technique is modified by sequentially prediluting the blood with an electrolyte solution that is similar to plasma and subsequently "ultrafiltering" it under high hydraulic pressures. This technique is more efficient than dialysis in removing solutes in the middle molecular range and results in patients who feel well and have little hemodynamic instability. Adjunctive techniques used with maintenance dialysis or for patients with significant residual renal function (a GFR of 5 to 10 mL/min) include the use of absorbent materials for solute removal. These absorbents may be used through direct action on the bloodstream (hemoperfusion), through regeneration of dialysate (REDY sorbent hemodialysis), or indirectly, through introduction into the gut.
In hemoperfusion, membrane-encapsulated activated charcoal is the absorbent whereas REDY sorbent dialysis systems use an enzyme sorbent cartridge for reprocessing dialysate. The REDY systems are widely used for patients who require specialized treatment and for home dialysis. A technique that uses the oral ingestion of absorbents such as activated charcoal is in its infancy although a similar technique using aluminum hydroxides is used conventionally for controlling phosphate levels.
▼ ORAL HEALTH CONSIDERATIONS
For the purposes of dental management, patients with renal disease can be categorized into two groups: patients with acute renal failure and patients with chronic progressing renal failure or end-stage renal failure who are undergoing dialysis.
Acute Renal Failure Patients
Acute renal failure (ARF) is most commonly observed in young healthy adults after injury to the renal tubules as a result of toxic agents, severe necrotizing glomerular disease, or complications of surgery, including hemorrhage and transfusion. Patients with ARF are not candidates for elective dental care, and some patients with ARF require the institution of dialysis therapy. In such cases, elective dental care should be deferred until the patient makes a complete renal recovery. Peritoneal dialysis generally poses no contraindications to dental treatment. The exceptions are in times of acute peritoneal infections, when elective care should be postponed.
Chronic Renal Failure and End-Stage Renal Disease Patients
Many patients with chronic renal disease have poor oral health. The results of a study assessing the dental needs of hemodialysis patients showed that 64% of these patients needed dental treatment and that the majority of these patients were not aware of the possible complications of dental neglect while on hemodialysis. 64 In addition to the more common reasons for not receiving routine dental treatment, these patients have limited access to dental care because many general dentists are reluctant to treat patients with severe systemic diseases. Because most dialysis centers refer their patients to general practitioners for most forms of treatment, it is important that more general dentists become familiar with the management problems associated with patients with ESRD who are undergoing dialysis.
Excessive bleeding and anemia are the two major hematologic conditions that most commonly affect patients with uremia and renal failure. Bleeding tendencies in these patients are attributed to a combination of qualitative and quantitative platelet defects, increased prostacycline activity, intrinsic coagulation defects, and capillary fragility. This hemorrhagic tendency can be magnified in the presence of uremia. Hemorrhagic episodes in the gingiva are not uncommon. Ulcerations and purpural or petechial lesions may be noted throughout the oral mucosa. Bruising after trauma is common, and hematoma formation should be expected after alveolectomy or periodontal surgery. Adjunctive hemostatic measures should be considered for patients who are at risk. DDAVP, the synthetic analogue of the antidiuretic hormone vasopressin, has been shown to be effective in the short-term management of bleeding in patients with renal failure. The effects of conjugated estrogen, used for longer-term hemostasis, commonly last for up to 2 weeks, compared to a few hours for DDAVP. Tranexamic acid (an antifibrinolytic agent) administered in the form of a mouthrinse or soaked gauze significantly reduces operative and postoperative bleeding. Meticulous surgical technique, primary closure, and local hemostatic aides such as microfibrillar collagen and oxidized regenerated cellulose should be used as the standards of care. Although rare, hemorrhagic effusions into the temporomandibular-joint space presenting as pain and swelling have been reported in a patient who was on dialysis and warfarin sodium therapy.
The timing of dental care for the patient who is undergoing dialysis has long been a source of discussion in the literature. Since dialysis will return hydration, serum electrolytes, urea nitrogen, and creatinine toward normal levels, arguments have been made for treating patients in a dental setting on the day of dialysis treatment. This argument is countered by the facts that patients often do not feel well immediately after undergoing dialysis and that they are heparinized. Ideally, elective dental procedures, as well as extractions and other surgery, should be done early in the dialysis cycle. At this point, the blood is free of uremic toxins, and the patient is far enough removed from dialysis to allow sufficient time after surgery for clotting before the next cycle and re-heparinization. Also, it is less likely that the patient will have a clotting defect that is due to uremia-related platelet dysfunction, which develops because of retained urea metabolites. A platelet count and complete blood count are important guides for the dental practitioner with regard to the management of bleeding tendencies and anemic conditions. However, since patients are physically and emotionally exhausted and do not feel well following dialysis treatments, elective dental procedures should be scheduled on nondialysis days, when patients are more likely to tolerate care.
Apart from serving as a potential site for infection, the arteriovenous site should never be jeopardized. The arm with the patent vascular access should be identified and noted on the patient's chart with instructions to avoid both intramuscular and intravenous injection of medication into this arm; nor should the access site be used as an injection site. The blood flow through the arm should not be impeded by requiring the patient to assume a cramped position or by using that arm to measure blood pressure. When the access site is located in a leg, the patient should avoid sitting for long periods. Obstructing venous drainage by compression at the groin or behind the knee must be avoided, especially because it tends to occur normally when the patient is in the sitting position. Such patients should be permitted to walk about for a few minutes every hour during a lengthy dental procedure.
Susceptibilty to infection is a serious concern for patients with uremia or ESRD who are undergoing hemodialysis. 65 These patients have an increased susceptibility to bacterial infections that results from altered cellular immunity secondary to the effects of uremic toxins combined with malnutrition from protein-restricted diets. Oral diseases and dental manipulation create bacteremias that may lead to significant morbidity and potential mortality in patients with renal failure who are undergoing hemodialysis. A majority of septicemic infections have been attributed to the vascular access site, but oral diseases such as periodontal disease, pulpal infection, and oral ulcerations, along with dental treatment, may provide microorganisms a convenient portal of entry the circulatory system. 66 Therefore, every effort should be made to eliminate potential sources of infection. Meticulous oral hygiene, including good home care, frequent oral health maintenance, and routine use of antifungal and antimicrobial oral rinses may reduce the risk of dentally induced infections.
Infective endocarditis is a serious concern in hemodialysis patients. Sepsis and bacterial endarteritis occur from infections at the access site by organisms seeded through punctures. Infective endocarditis has been reported in patients with access site grafts on hemodialysis after receiving dental treatment. The incidence of infective endocarditis in patients undergoing hemodialysis is 2.7%. In those patients with a history of vascular access site infection, the incidence increases to 9.0%. Streptococcus viridans accounts for almost one-third of the cases of infective endocarditis whereas staphylococcal organisms such as Staphylococcus epidermidis and Staphylococcus aureus account for the majority of cases. The cause of endocarditis in these patients is debatable but seems to be related to a combination of vascular access and intrinsic cardiaovalvular pathology. The presence of an arteriovenous shunt or synthetic graft (fistula) sutured in place increases the risk for infective colonization at the suture lines or at the surface discrepancies between normal arterial intima and the so-called prosthetic pseudointima. These sites may provide a nidus for intravascular lodgment of bacteria, leading to the persistence of an otherwise transient bacteremia (such as one resulting from dental manipulation), with subsequent endarteritis, embolization, and possible endocardial infection. 67 A period of high susceptibility to infection is usually seen within the first 3 months after implantation (risk is highest in the first 3 weeks), after which there is a gradual decline in risk. This reduced risk is possibly caused by an "insulating effect" of the developing pseudointima and endothelialization.
Endocarditis infection is more likely to affect previously abnormal cardiac valves; yet, there is a high incidence of endocarditis in hemodialysis patients with no previously demonstrated valvulopathy. A possible explanation may lie in the theory that changes in fluid volume with uremia and hemodialysis may affect blood flow through the heart and cardiac function, creating mechanical stresses on the valves that play a role in the development of infective endocarditis. Therefore, according to the American Heart Association's protocol for prevention of infective endocarditis, antimicrobial premedication should be used routinely prior to appropriate dental procedures.
The choice of antibiotic depends on many variables but is primarily based on the type of microorganisms that have been cultured at the site of manipulation. In patients who were reported to have acquired infective endocarditis after dental treatment, either viridans streptococci or Enterococcus spp were the causative agents. This indicates a prophylactic regimen of either (1) amoxicillin or clindamycin or (2) a broad-spectrum antibiotic such as oral clarithromycin (as recommended by the American Heart Association) or IV vancomycin in patients with hypersensitivity to penicillin or clindamycin. Limited insurance reimbursement for vancomycin infusion may limit many patients' access to this therapy.
Because these patients are exposed to a large number of blood tranfusions and exchanges and also because of their renal failure-related immune dysfunction, they are at greater risk of hepatotropic viral infections (such as hepatitis B and C), HIV infection, and tuberculosis. Many patients with renal disease may have viral hepatitis without clinical manifestations. In these patients, the disease tends to run a chronic and persistently active (although subclinical) course. With the advent of prophylactic immunoglobulin and the hepatitis B vaccine, the number of dialysis unit outbreaks of hepatitis has decreased; however, the dialysis patient should still be considered to be in a high-risk group. The prevalence of hepatitis C virus (HCV) infection in dialysis patients ranges from 3.9 to 71%. 68, 69 Patients undergoing dialysis should be encouraged to undergo periodic testing for hepatitis infectivity and for HIV antibody. Hemodialysis patients with accompanying conditions such as HIV disease, viral hepatitis (and associated liver dysfunction), and tuberculosis (TB) have complicating issues that affect the provision of dental care. CRF patients who are on hemodialysis have been reported to be at increased risk of developing tuberculosis. 70 (The dental management of patients with HIV infection, TB, and viral hepatitis is discussed in Chapter 20.) As a result of changes in fluid volume, sodium retention, and the presence of vascular access, these patients are commonly affected by a host of cardiovascular conditions. Often, hypertension, postdialysis hypotension, congestive heart failure, and pulmonary hypertension can be seen in patients who are undergoing hemodialysis. 71 Hypertension in the presence of ESRD can lead to accelerated atherosclerosis. Although the medical management of these patients includes the aggressive use of antihypertensive agents, the dental practitioner should obtain blood pressure readings at every visit, prior to and during procedures. Avoiding excessive stress in the dental chair is important to minimize intraoperative elevations of systolic pressure. The use of sedative premedication should be considered for patients who are to undergo stressful procedures. Hypotension resulting from fluid depletion is a common complication of hemodialysis and occurs in up to 30% of dialysis sessions. Cerebrovascular accidents, angina, fatal dysrhythmias, and myocardial infarction are less common but serious sequelae of hemodialysis and most commonly present during or immediately following dialysis. Therefore, elective dental care should be performed on nondialysis days, when the patients are best able to tolerate treatment.
Pharmacotherapeutics are a serious concern for dentists treating patients who have renal disease. Most drugs are excreted at least partially by the kidney, and renal function affects drug bioavailability, the volume of drug distribution, drug metabolism, and the rate of drug elimination. The dentist can obviate problems of drug reactions and further renal damage by following simple principles related to drug administration and by altering dosage schedules according to the amount of residual renal function. Many ordinarily safe drugs must not be administered to the uremic patient, and many others must be prescribed over longer intervals (Table 15-6 ). The plasma half-lives of medications that are normally eliminated in the urine are often prolonged in renal failure and are effectively reduced by dialysis. Even drugs that are metabolized by the liver can lead to increased toxicity because the diseased kidneys fail to excrete them effectively. Theoretically, a 50% decrease in creatinine clearance corresponds to a twofold increase in the elimination half-life of any medication excreted fully by the kidneys. For drugs that are partially excreted by the kidneys, the change in plasma half-life is proportionally less. For most drugs, it is proper to give a loading dose similar to that given to patients without renal disease; this provides a clinically desirable blood concentration that can be sustained by the necessary dosage adjustments. Whenever reliable blood drug level measurements are available, they can be used to monitor therapy. In the absence of precise blood levels, the best guide to therapy is carefully obtained data on biologic halflives of drugs in humans with varying degrees of renal failure.
Certain drugs are themselves nephrotoxic and should be avoided. Particular medications may be metabolized to acid Determine dialysis schedule and treat on day after dialysis. Consult with patient's nephrologist for recent laboratory tests and discussion of antibiotic prophylaxis. Identify arm with vascular access and type; notate in chart and avoid taking blood pressure measurement/injection of medication on this arm. Evaluate patient for hypertension/hypotension. Institute preoperative hemostatic aids (DDAVP, conjugated estrogen) when appropriate. Determine underlying cause of renal failure (underlying disease may affect provision of care). Obtain routine annual dental radiographs to establish presence and follow manifestations of renal osteodystrophy. Consider routine serology for HBV, HCV, and HIV antibody. Consider antibiotic prophylaxis when appropriate. Consider sedative premedication for patients with hypertension.
During treatment
Perform a thorough history and physical examination for presence of oral manifestations. Aggressively eliminate potential sources of infection/bacteremia. Use adjunctive hemostatic aids during oral/periodontal surgical procedures. Maintain patient in a comfortable uncramped position in the dental chair. Allow patient to walk or stand intermittently during long procedures. and nitrogenous waste or may stimulate tissue catabolism. NSAIDs may induce sodium retention, impair the action of diuretics, prevent aldosterone production, affect renal artery perfusion, and cause acidosis. Tetracyclines and steroids are antianabolic, increasing urea nitrogen to approximately twice the baseline levels. Other drugs, such as phenacetin, are nephrotoxic and put added strain on an already damaged kidney (Table 15-7) . The challenge for dentists in prescribing medications is to maintain a therapeutic regimen within a narrow range, avoiding subtherapeutic dosing and toxicity. The safety of a fluoridated community water supply for patients undergoing hemodialysis has been questioned in regard to whether such water is a contributing factor to the incidence of renal osteodystrophy, fluoride toxicity, and fluorosis. There is no satisfactory evidence that the fluoride content of fluoridated drinking water is harmful to patients with severe renal disease. Dialysis patients, however, should receive dialysates that are water-purified and deionized. No studies have reported on the dental use of topical fluoride in patients with renal disease or on any related problems. If a patient with renal disease needs fluoride supplements for caries control (particularly because of diminished salivary flow), the preferred route should be fluoride rinses until more definitive studies are carried out.
